Sección de Química Médica

Inicio | Investigación e innovación | Programas Científicos | Programa de Terapias Experimentales | Sección de Química Médica

Investigadores Científicos

  • Ana B. García
  • Cristina Ana Gómez
  • Esther González
  • Sonsoles Rodríguez
  • Terry Pascal Tomakinian
  • Carmen Varela

Medicinal Chemistry (MedChem) is a scientific discipline concerned with the design and synthesis of bioactive molecules to address unmet medical needs or to improve existing drugs. The discipline combines expertise in organic chemistry with knowledge of ligand-receptor interactions and pharmacology to design and modify the structure and properties of molecules, to improve potency and drug-like properties.

The Medicinal Chemistry Section is part of the multidisciplinary Experimental Therapeutics Programme (ETP), which focuses on early drug discovery activities. The ETP is integrated into the CNIO’s structure, and acts as a bridge between basic research groups in cancer biology, which identify innovative targets that play a relevant role in cancer, and the pharmaceutical industry. Our goal is to generate molecules against these cancer targets and to demonstrate their efficacy and mechanism of action in animal models (in vivo proof of concept). This allows us to translate the results obtained in basic research laboratories into potential drugs that contribute to the understanding of cancer biology, as well as to increase the interest of the pharmaceutical industry to develop new therapies.

Publicaciones

    SELECT dxsjj_posts.* FROM dxsjj_posts LEFT JOIN dxsjj_postmeta ON ( dxsjj_posts.ID = dxsjj_postmeta.post_id ) LEFT JOIN dxsjj_postmeta AS mt1 ON ( dxsjj_posts.ID = mt1.post_id AND mt1.meta_key = 'factor_impacto' ) LEFT JOIN dxsjj_postmeta AS mt2 ON ( dxsjj_posts.ID = mt2.post_id ) LEFT JOIN dxsjj_postmeta AS mt3 ON ( dxsjj_posts.ID = mt3.post_id ) LEFT JOIN dxsjj_postmeta AS mt4 ON ( dxsjj_posts.ID = mt4.post_id ) WHERE 1=1 AND ( ( dxsjj_postmeta.meta_key = 'factor_impacto' OR mt1.post_id IS NULL ) AND mt2.meta_key = 'autores' AND ( mt3.meta_key = 'id_grupos' AND mt3.meta_value LIKE '{560f605aac862353640cca5c6d96a8ddde8e9ad4db52990e751b250b44fab198}50008996{560f605aac862353640cca5c6d96a8ddde8e9ad4db52990e751b250b44fab198}' ) AND ( mt4.meta_key = 'anyo' AND CAST(mt4.meta_value AS SIGNED) >= '2020' ) ) AND dxsjj_posts.post_type = 'cnio_publication' AND ((dxsjj_posts.post_status = 'publish')) GROUP BY dxsjj_posts.ID ORDER BY CAST(mt4.meta_value AS SIGNED) DESC, CAST(dxsjj_postmeta.meta_value AS SIGNED) DESC, CAST(mt2.meta_value AS CHAR) ASC

  • Álvarez RM, García AB, Riesco-Fagundo C, Martín JI, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Oyarzabal J, Di Geronimo B, Lorenzo M, Albarrán MI, Cebriá A, Cebrián D, Martínez-González S, Blanco-Aparicio C, Pastor J (2021). Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors.. Eur J Med Chem 211, 113109. Publicación CNIO.
  • Martínez-González S, Alvarez RM, Martín JI, García AB, Riesco-Fagundo C, Varela C, Rodríguez Hergueta A, González Cantalapiedra E, Albarrán MI, Gómez-Casero E, Cebriá A, Aguirre A, Ajenjo N, Cebrián D, Geronimo B, Cunningham D, O'Neill M, Dave HPG, Blanco-Aparicio C, Pastor J (2021). Macrocyclization as a source of desired polypharmacology. Discovery of triple PI3K/mTOR/PIM inhibitors.. ACS Med Chem Lett 12, 1794-1801. Publicación CNIO.
  • Lynch CJ, Bernad R, Martínez-Val A, Shahbazi MN, Nóbrega-Pereira S, Calvo I, Blanco-Aparicio C, Tarantino C, Garreta E, Richart-Ginés L, Alcazar N, Graña-Castro O, Gómez-Lopez G, Aksoy I, Muñoz-Martín M, Martinez S, Ortega S, Prieto S, Simboeck E, Camasses A, Stephan-Otto Attolini C, Fernandez AF, Sierra MI, Fraga MF, Pastor J, Fisher D, Montserrat N, Savatier P, Muñoz J, Zernicka-Goetz M, Serrano M (2020). Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases. Nat Cell Biol 22, 1223-1238. Publicación CNIO.
  • Mohlin S, Hansson K, Radke K, Martinez S, Blanco-Apiricio C, Garcia-Ruiz C, Welinder C, Esfandyari J, O'Neill M, Pastor J, von Stedingk K, Bexell D (2020). Anti?tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL?302 in neuroblastoma. EMBO Mol Med 12, e11749. Publicación CNIO.
  • Kennedy SP, O'Neill M, Cunningham D, Morris PG, Toomey S, Blanco-Aparicio C, Martinez S, Pastor J, Eustace AJ, Hennessy BT (2020). Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.. Oncogene 39, 3028-3040. Publicación CNIO.
  • Cash TP, Alcalá S, Rico-Ferreira MDR, Hernández-Encinas E, García J, Albarrán MI, Valle S, Muñoz J, Martínez-González S, Blanco-Aparicio C, Pastor J, Serrano M, Sainz B Jr (2020). Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells. Cancers 12, 1790. Publicación CNIO. Open Access Open Access
  • Klett J, Gómez-Casero E, Méndez-Pertuz M, Urbano-Cuadrado M, Megias D, Blasco MA, Martínez S, Pastor J, Blanco-Aparicio C (2020). Screening protocol for the identification of modulators by immunofluorescent cell-based assay. Chem Biol Drug Des 95, 66-78. Publicación CNIO.

Subir